VIVUS (NASDAQ:VVUS) not only beat its competitors, Arena Pharmaceuticals (NASDAQ:ARNA) and Orexigen Therapeutics (NASDAQ: OREX), in making its obesity drug the first to reach patients -- it's also the first of this trio to report its Q3 earnings.

VIVUS posted its Q3 report before the market opened this morning, and unfortunately for shareholders, the company's results didn't meet the market's expectations. The company's net revenue was expected to top $300,000, but the drugmaker only raked in a little over $40,000. Earnings also took a bigger hit than expected, and VIVUS' shares subsequently plunged almost 25% today.

In the following video, health care analysts Max Macaluso and David Williamson discuss these stagnant sales and three ways that VIVUS can boost revenue in upcoming quarters.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.